Industry Developments

BMI View: We continue to highlight the economic and political challenges faced by Belarus' domestic pharmaceutical industry and the potential for internal developments to affect the... 2011-10-24

BMI View: Our weak 2012 outlook for Slovakia's pharmaceutical market has been maintained with the passage of key drug policy reforms in September, prior to the fall of Iveta Radicová's... 2011-10-20

BMI View: Poland has a well-structured medicine pricing and reimbursement system and has a relatively transparent approval process. The government plays a significant role in the funding... 2011-10-17

BMI View: European drugmakers continue to dominate Russia's pharmaceutical market. While there is evidence that US firms have been increasing their involvement and focus in the country,... 2011-10-14

BMI View: The introduction of a revised claw-back mechanism in Romania has angered drugmakers operating in the market. BMI believes the current form of the legislation is overly simplistic... 2011-10-13

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: Small changes to Hungary's 2012 budget plan are moderately good news for drugmakers. However, longer-term savings targets have been maintained and the impact of legislated... 2011-10-11

BMI View: With a high probability of imminent default, the outlook for Greece's pharmaceutical and healthcare market is worsening, and the uncertainty of how and when a default could... 2011-10-05

BMI View: While it is likely that the sale of Chinese-made pharmaceuticals in Russia will continue to increase in the coming years, we do not believe these producers offer the Russian... 2011-09-19

BMI View: Macedonia's pharmaceutical market is projected to return stable but unspectacular growth over the next five years. The current low level of drug consumption and increasing... 2011-09-15